APOC3 and diabetes mellitus: Finally, the ratios between oxidised and non‐oxidised proteoforms (especially those of ApoC‐III) showed a perfect discriminatory capability between MASLD and control sera, suggesting a promising role as a non‐invasive biomarker for this condition: we think that the ApoC‐III oxidised ratios could be used to refine MASLD prediction in patients with risk factors (e.g. diabetes); the combination of these biomarkers with non‐invasive predictors of fibrosis (e.g. FIB4 or Fibroscan) will restrict the number of patients to be referred for further hepatology screening and surveillance.